| Name | Title | Contact Details |
|---|
Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO).
Improving the lives of people with severe illness or injury takes more than skill and compassion - it takes innovation. A national leader in long term acute care, LifeCare was built on the belief that early and aggressive intervention, coupled with a personalized treatment plan that encompasses body, mind and soul, can maximize a patient`s potential for recovery. Our multi-disciplinary treatment teams are directed by highly-trained, committed physicians and include healthcare professionals involved in all aspects of a patient`s care: nurses, respiratory therapists, physical medicine specialists, radiologists, pharmacists, dietitians and case managers. Our philosophy has impacted the lives of thousands of LifeCare patients, resulting in improved outcomes, shorter hospital stays and more cost-effective treatment. Based in Plano, Texas, the LifeCare Family of Hospitals includes both freestanding and "hospital-in-hospital" acute care hospitals designed to treat medically complex patients who require acute care hospital services for an extended period of time. Currently, our network includes 24 locations in 9 states.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse and experienced team of scientists and business leaders who are committed to bringing life-changing and life-saving therapeutics to patients worldwide.
With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM as the next generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema. The potential to liberate patients from legal blindness to a much improved quality of life sustained by self-sufficient functional vision propels and accelerates our efforts.